[1]于 翔,成思航,曹 磊,等.术前全身免疫炎症指数与DEB-TACE治疗肝癌患者预后相关性分析[J].介入放射学杂志,2021,30(05):461-465.
　YU Xiang,CHENG Sihang,CAO Lei,et al.Analysis of the correlation between the preoperative systemic immune inflammatory index and the prognosis in liver cancer patients receiving transarterial chemoembolization with CalliSpheres drug-eluting beads[J].journal interventional radiology,2021,30(05):461-465.
点击复制

术前全身免疫炎症指数与DEB-TACE治疗肝癌患者预后相关性分析()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年05
页码:
461-465
栏目:
肿瘤介入
出版日期:
2021-05-25

文章信息/Info

Title:
Analysis of the correlation between the preoperative systemic immune inflammatory index and the prognosis in liver cancer patients receiving transarterial chemoembolization with CalliSpheres drug-eluting beads
作者:
于 翔;  成思航;  曹 磊;  杨 龙;  顾 露;  谢 坪
Author(s):
YU Xiang;  CHENG Sihang;  CAO Lei;  YANG Long;  GU Lu;  XIE Ping.
Department of Radiology， Sichuan Provincial People’s Hospital，Sichuan Provincial Academy of Medical Sciences， Chengdu， Sichuan Province 610041， China
关键词:
【关键词】 肝癌;  中性粒细胞;  淋巴细胞;  血小板;  免疫炎症指数;  药物洗脱微球
文献标志码:
A
摘要:
【摘要】 目的 评估全身免疫炎症指数（systemic immune inflammatory index，SII）对CalliSpheres药物洗脱微球-经导管动脉化疗栓塞术（DEB-TACE）治疗肝癌患者的预测价值。方法 回顾性分析2016年10月至2018年10月四川省人民医院介入科收治肝癌患者65例，均接受CalliSpheres-经导管动脉栓塞术，绘制受试者工作特征（ROC）曲线并计算SII最佳临界值，利用单因素、多因素回归分析、Kaplan-Meier生存曲线判断术前SII对患者生存期的预后价值。结果 SII的ROC曲线下面积为0.69，术前SII截断值为212.2，多因素Cox回归分析发现肿瘤最大径≥5 cm、TACE前SII＞212.2是总生存率（OS）的重要预测指标，SII≤212.2组，＜3个月，3～6个月，6～12个月，＞12个月的生存率分别是100%，88.2%，58.8%，35.3%；SII＞212.2组，同期生存率分别是87.5%，66.7%，41.7%，17.2%。结论 在临床实践中， SII升高作为无创、低成本、易评估和可重复的参数，可作为CalliSpheres DEB-TACE治疗肝癌患者总体生存预测因素。

参考文献/References:

［1］ Zhu XD， Zhang JB， Zhuang PY， et al. High expression of macrophage colony- stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepato- cellular carcinoma［J］. J Clin Oncol， 2008， 26： 2707-2716.
［2］ Ding T， Xu J， Wang F， et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepato- cellular carcinoma after resection［J］. Hum Pathol， 2009， 40： 381-389.
［3］ Waidmann O， Koberle V， Bettinger D， et al. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma［J］. J Hepatol， 2013， 59： 769-779.
［4］ Chen JH， Zhai ET， Yuan YJ， et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer［J］. World J Gastroenterol， 2017， 23： 6261.
［5］ Diao PF， Wu YP， Li J， et al. Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection［J］. J Transl Med， 2018， 16： 365.
［6］ Jomrich G，Gruber ES， Winkler D， et al. Systemic immune-inflammation index（SII） predicts poor survival in pancreatic cancer patientsundergoing resection［J］. J Gastrointest Surg， 2020， 24：610- 618.
［7］ Bruix J， Sherman M. Management of hepatocellular carcinoma［J］. Hepatology， 2005， 42： 1208-1236.
［8］ Simioni C， Martelli AM， Cani A， et al. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphos- phorylated AKT-1 and synergizes with conventional chemotherapy［J］. Oncotarget， 2013， 4： 1496-1506.
［9］ Hanahan D， Weinberg RA. Hallmarks of cancer： the next generation［J］. Cell， 2011， 144： 646- 674.
［10］ Villanueva A， Longo DL. Hepatocellular carcinoma［J］. N Engl J Med， 2019， 380： 1450-1462.
［11］ Grivennikov SI， Greten FR， Karin M. Immunity， inflammation， and cancer［J］. Cell， 2010， 140：883- 899.
［12］ MantovaniA，Allavena P， Sica A， et al. Cancer- related inflam- mation［J］. Nature， 2018， 454：436- 444.
［13］ Hu B， Yang XR， Xu Y， et al. Systemic Immune-Inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］. Clin Cancer Res， 2014， 20： 6212-6222.
［14］ Wojtukiewicz MZ， Sierko E， Hempel D， et al. Platelets and cancer angiogenesis nexus［J］. Cancer Metastasis Rev， 2017， 36： 249-262.
［15］ 邹伟婕，陈 立，周 实． 天冬氨酸转移酶与中性粒细胞比值对肝癌患者TACE治疗预后的影响［J］． 介入放射学杂志， 2017， 26：705-711．
［16］ Ocana A， Nieto-Jimenez C， Pandiella A， et al. Neutrophils in cancer： prognostic role and therapeutic strategies［J］. Mol Cancer， 2017， 16： 137.
［17］ Wang D， Bai N， Hu X， et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC［J］. Peer J， 2019， 7： e7132.
［18］ Karakousis G， Yang R， Xu X. Circulating melanoma cells as a predictive biomarker［J］. J Invest Dermatol， 2013， 133： 1460-1462.
［19］ Sun B， Karin M. Obesity， inflammation， and liver cancer［J］. J Hepatol， 2012， 56：704-713.
［20］ Jiang D， Liu Y， Wang H， et al.Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma［J］. Sci Rep， 2017， 7：44823.
［21］ Gao LW， Hua Z， Bin Z， et al. Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer［J］. Oncotarget， 2017， 8： 15632-15641.
［22］ Zuo MX， Huang JH. The history of interventional therapy for liver cancer in China［J］. J Intervent Med， 2018， 1： 70-76.
［23］ Paramanathan A， Saxena A， Morris DL. A systematic review and meta- analysis on the impact of pre- operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours［J］. Surg Oncol， 2014， 23： 31-39.
［24］ Wan YL， Eric CL. Loco-regional intervention for hepatocellular carcinoma［J］. J Intervent Med， 2019， 2： 43- 46.
［25］ Scilla KA， Bentzen SM， Lam VK， et al. Neutrophil‐lymphocyte ratio is a prognostic marker in patients with locally advanced （stage ⅢA and ⅢB） Non‐small cell lung cancer treated with combined modality therapy［J］. Oncologist， 2017， 22： 737-742.
［26］ Wang BL， Tian L， Gao XH， et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection［J］. Clin Chem Lab Med， 2016， 54： 1963-1969.

相似文献/References:

[1]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(05):348.
[2]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(05):322.
[3]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(05):968.
[4]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(05):1010.
[5]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(05):75.
[6]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(05):78.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(05):682.
[8]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
　LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(05):1035.
[9]徐 阳,臧 爽,陈路锋,等.Logistic回归及ROC曲线综合评价血生化指标对肝癌TACE术后发热的预测价值 [J].介入放射学杂志,2013,(06):513.
　XU Yang,ZANG Shuang,CHEN Lu? feng,et al. Combination evaluation of plasma biochemical indexes with Logistic regression and ROC analysis in predicting hyperthermia after transcatheter hepatic arterial chemoembolization for liver cancer[J].journal interventional radiology,2013,(05):513.
[10]彭国文,李晓群. 射频消融及组合方案治疗特殊/高危部位肝癌的中远期疗效[J].介入放射学杂志,2013,(06):525.
　PENG Guo? wen,LI Xiao? qun.. The mid?蛳 to?蛳 long term efficacy of radiofrequency ablation together with combination regimen for the treatment of hepatic carcinomas located at special or high?蛳 risk regions[J].journal interventional radiology,2013,(05):525.

备注/Memo

备注/Memo:
（收稿日期：2020-03-03）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2021-05-20